Research publications

Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity, Fougeroux C. et alNat Commun 2021

Neutralising antibodies block the function of Rh5/Ripr/CyRPA complex during invasion of Plasmodium falciparum into human erythrocytes, Healer J, et al. Cell Microbiol 2019.

First-in-human, Randomized, Double-blind Clinical Trial of Differentially Adjuvanted PAMVAC, A Vaccine Candidate to Prevent Pregnancy-associated Malaria, Mordmüller B, et al. Clin Infect Dis 2019.

Structure of Plasmodium falciparum Rh5-CyRPA-Ripr invasion complex, Wong W, et al. Nature 2019.

Structural basis for recognition of the malaria vaccine candidate Pfs48/45 by a transmission blocking antibody, Lennartz F, et al. Nat Commun 2018.

Production, quality control, stability, and potency of cGMP-produced Plasmodium falciparum RH5.1 protein vaccine expressed in Drosophila S2 cells, Jin J, et al. NPJ Vaccines 2018.

Virus-like particle display of HER2 induces potent anti-cancer responses, Palladini A, et al. Oncoimmunology 2018.

Production of full-length soluble Plasmodium falciparum RH5 protein vaccine using a Drosophila melanogaster Schneider 2 stable cell line system, Hjerrild KA, et al. Sci Rep 2016.

Bacterial superglue enables easy development of efficient virus-like particle based vaccines, Thrane S, et al. J Nanobiotechnology 2016.

The Influence of Sub-Unit Composition and Expression System on the Functional Antibody Response in the Development of a VAR2CSA Based Plasmodium falciparum Placental Malaria Vaccine, Nielsen MA, et al. PLoS One 2015.

A Novel Virus-Like Particle Based Vaccine Platform Displaying the Placental Malaria Antigen VAR2CSA, Thrane et al, PLOS One 2015.

Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies, Wright KE, et al. Nature 2014.